Introduction. Severe COVID-19 is characterized by a dysregulated immune response driven in part by interleukin-6 (IL-6), leading to hyperinflammation and adverse clinical outcomes. Tocilizumab, an IL-6 receptor antagonist, has been widely used to mitigate this response; however, real-world data on biomarker dynamics following treatment remain limited, particularly in underrepresented regions.
The objective of the study was to evaluate the temporal dynamics of inflammatory biomarkers and their association with clinical outcomes following biomarker-guided tocilizumab therapy in patients with severe COVID-19.
Materials and methods. This retrospective study included 20 adult patients with severe COVID-19 treated with tocilizumab in a tertiary care center in Georgia, between 2021 and 2022. Serial measurements of interleukin (IL)-6, C-reactive protein (CRP), ferritin, and lactate dehydrogenase (LDH) were analyzed at baseline, peak, and final timepoints. Paired statistical tests and subgroup comparisons between survivors and non-survivors were performed.
Results. CRP levels decreased significantly following tocilizumab administration (p < 0.001), with all patients demonstrating values below baseline at final assessment. IL-6 levels increased significantly at peak (p < 0.01), consistent with receptor blockade, and subsequently declined, with normalization observed in 65% of patients. Ferritin and LDH showed marked post-treatment increases followed by partial resolution, without statistically significant changes at final assessment (p > 0.05). Non-survivors exhibited persistently elevated ferritin and LDH levels compared to survivors. Overall mortality was 20%, and all surviving patients demonstrated clinical improvement with de-escalation of oxygen support.
Conclusions. Tocilizumab administration during the immune phase of COVID-19 is associated with rapid suppression of CRP and characteristic IL-6 dynamics, reflecting effective modulation of IL-6-mediated inflammation. Persistent elevation of ferritin and LDH suggests involvement of IL-6-independent pathways and may be associated with adverse outcomes. These findings support the role of biomarker-guided immunomodulatory therapy and highlight the need for further studies targeting multiple inflammatory pathways.
Keywords: COVID-19, tocilizumab, interleukin-6, biomarkers, immunomodulation.
Chapidze Emergency Cardiology Center, Tbilisi, Georgia
Address: N. Javakhishvili Str. 1, 0159, Tbilisi, Georgia
Email: lelakopala@gmail.com; Phone: +9955595510545
